8:17 AM
 | 
Oct 23, 2017
 |  BC Extra  |  Clinical News

FDA issues CRL for Antares' hypogonadism candidate

Antares Pharma Inc. (NASDAQ:ATRS) said FDA issued a complete response letter for Xyosted to treat hypogonadism.

The company said the CRL raised concerns over a clinically meaningful...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >